Record Preliminary Revenue Achieved by OrthoPediatrics Corp.
OrthoPediatrics Corp. has made headlines by achieving a remarkable preliminary unaudited net revenue of approximately $205 million for the full year of 2024. This milestone reflects an impressive growth rate of 38% year-over-year. The enthusiasm surrounding this surge in revenue is palpable, especially as the company also outlines optimistic financial projections for 2025.
Significant Business Milestones in 2024
In the fourth quarter of 2024, OrthoPediatrics successfully aided more than 34,000 children, bringing the total number of children supported since its inception to over 1.1 million. This achievement highlights the organization's unwavering commitment to meeting the needs of pediatric patients and their families. The company recorded a preliminary net revenue of $52.7 million for the fourth quarter alone, showcasing a 40% increase compared to the same period in 2023. Such growth can be attributed to the robust demand for its specialized pediatric orthopedic products.
Revenue Breakdown
The breakdown of revenue shows that domestic sales are projected to reach $161.1 million, signaling a 45% growth, while international sales are expected to contribute approximately $43.6 million, marking a 16% annual growth. This dual growth strategy demonstrates the company's ability to expand its market presence both locally and globally.
Financial Guidance for 2025
Looking ahead, OrthoPediatrics has issued financial guidance projecting 2025 revenue to fall between $235 million and $242 million, representing a growth of 15% to 18%. In addition to this positive revenue outlook, the company anticipates its annual set deployment to reach around $15 million, alongside an expected adjusted EBITDA range of $15 million to $17 million for the year.
Continued Growth Strategy
David Bailey, President & CEO of OrthoPediatrics, expressed confidence in the company’s performance across various business segments, particularly in trauma, deformity, and scoliosis treatment areas. He acknowledged that the specialty bracing market stands as a significant growth opportunity, positioning the company well to leverage this segment's potential as it expands its operations.
Quarterly and Annual Results Announcement
The company is expected to release its complete financial results for both the fourth quarter and the full year 2024 in early March. These results will provide further insights into the financial health and operational success of OrthoPediatrics.
Emphasis on Pediatric Orthopedics
Founded in 2006, OrthoPediatrics is a leader in advancing pediatric orthopedic solutions. With an extensive product range, the company continues to focus on improving the quality of care for children with orthopedic conditions. Its offerings include innovative solutions across three major areas: trauma and deformity, scoliosis, and sports medicine. The dedication to this niche market underscores the company's mission to enhance the lives of young patients.
Frequently Asked Questions
What is the reported revenue for OrthoPediatrics Corp. in 2024?
The preliminary unaudited net revenue for OrthoPediatrics in 2024 is reported to be approximately $205 million.
How many children has OrthoPediatrics assisted since its inception?
OrthoPediatrics has provided assistance to over 1.1 million children since it was founded.
What are the financial projections for OrthoPediatrics for 2025?
The company expects its revenue for 2025 to range between $235 million and $242 million.
What areas does OrthoPediatrics focus on for its products?
The company specializes in pediatric orthopedics, focusing on trauma, deformity, scoliosis, and sports medicine.
When will OrthoPediatrics release its full-year financial results?
The full-year financial results are set to be released in early March.
